Open-source automated insulin delivery systems (OS-AIDs) in a pediatric population with type 1 diabetes in a real-life setting: the AWeSoMe study group experience.
Adolescents
Automated insulin delivery system
Open-source
Pediatric
Type 1 diabetes
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
04
02
2023
accepted:
09
05
2023
medline:
28
6
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
The use of open-source automated insulin delivery systems (OS-AIDs), for the management of type 1 diabetes (T1D), has increased over recent years in all age groups. Real-life data has demonstrated the safety and efficacy of these systems, however, studies in the pediatric population remain limited. In this study, we aimed to examine the effect of transition to an OS-AIDs on glycemic parameters, and on several aspects related to quality of life. In addition, we aimed to characterize the socioeconomic position of families who chose this treatment modality, assess their motivations to do so, and evaluate treatment satisfaction. In this multi-center observational real-life study from the AWeSoMe Group, we compared glycemic parameters of 52 individuals with T1D (56% males, mean diabetes duration 4.2 ± 3.9 years), from the last clinic visit prior to OS-AIDs initiation to the most recent clinic visit while using the system. Socioeconomic position (SEP) index was retrieved from the Israel Central Bureau of Statistics. Caregivers completed questionnaires assessing reasons for system initiation and treatment satisfaction. Mean age at OS-AIDs initiation was 11.2 ± 4 years, range 3.3-20.7 years with a median usage duration of 11.1 months (range 3-45.7). Mean SEP Index was 1.033 ± 0.956 (value range: -2.797 to 2.590). Time in range (TIR) of 70 to 180 mg/dl increased from 69.0 ± 11.9 to 75.5 ± 11.7%, (P < 0.001), and HbA1c decreased from 6.9 ± 0.7 to 6.4 ± 0.6%, (P < 0.001). Time in tight range (TITR) of 70 to 140 mg/dl increased from 49.7 ± 12.9 to 58.8 ± 10.8% (P < 0.001). No episodes of severe hypoglycemia or DKA were reported. Reduction in diabetes burden and sleep quality improvement were the main reasons for OS-AID initiation. In our cohort of youth with T1D, the transition to an OS-AID resulted in greater TIR and less severe hypoglycemia regardless of age, diabetes duration or SEP, which was found to be above average. The overall improvement in glycemic parameters in our study population with excellent baseline glycemic control, provides additional evidence of beneficence and efficacy of OS-AIDs in the pediatric population.
Identifiants
pubmed: 37222881
doi: 10.1007/s12020-023-03398-4
pii: 10.1007/s12020-023-03398-4
doi:
Substances chimiques
Insulin
0
Hypoglycemic Agents
0
Blood Glucose
0
Types de publication
Multicenter Study
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-269Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
N.C. Foster, R.W. Beck, K.M. Miller, M.A. Clements, M.R. Rickels, L.A. DiMeglio, D.M. Maahs, W.V. Tamborlane, R. Bergenstal, E. Smith, B.A. Olson, S.K. Garg, State of Type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol. Ther. 21(2), 66–72 (2019). https://doi.org/10.1089/dia.2018.0384
doi: 10.1089/dia.2018.0384
pubmed: 30657336
pmcid: 7061293
A. Addala, M. Auzanneau, K. Miller, W. Maier, N. Foster, T. Kapellen, A. Walker, J. Rosenbauer, D.M. Maahs, R.W. Holl, A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care 44(1), 133–140 (2021). https://doi.org/10.2337/dc20-0257
doi: 10.2337/dc20-0257
pubmed: 32938745
R.A. Lal, L. Ekhlaspour, K. Hood, B. Buckingham, Realizing a closed-loop (artificial pancreas) system for the treatment of type 1 diabetes. Endocr. Rev. 40(6), 1521–1546 (2019). https://doi.org/10.1210/er.2018-00174
doi: 10.1210/er.2018-00174
pubmed: 31276160
pmcid: 6821212
D.M. Lewis, Do-it-yourself artificial pancreas system and the OpenAPS movement. Endocrinol. Metab. Clin. North Am. 49(1), 203–213 (2020). https://doi.org/10.1016/j.ecl.2019.10.005
doi: 10.1016/j.ecl.2019.10.005
pubmed: 31980119
K. Braune, R.A. Lal, L. Petruzelkova, G. Scheiner, P. Winterdijk, S. Schmidt, L. Raimond, K.K. Hood, M.C. Riddell, T.C. Skinner, K. Raile, S. Hussain; Network OIHP, Group OLA, Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol. 10(1), 58–74 (2022). https://doi.org/10.1016/S2213-8587(21)00267-9
doi: 10.1016/S2213-8587(21)00267-9
pubmed: 34785000
Central Bureau of Statistics (2013). Characterisation and classification of geographical units by the socio-economic level of the population (2008). https://www.cbs.gov.il/he/publications/DocLib/2013/1530/pdf/e_print.pdf
T. Battelino, T. Danne, R.M. Bergenstal, S.A. Amiel, R. Beck, T. Biester, E. Bosi, B.A. Buckingham, W.T. Cefalu, K.L. Close, C. Cobelli, E. Dassau, J.H. DeVries, K.C. Donaghue, K. Dovc, F.J. Doyle III, S. Garg, G. Grunberger, S. Heller, L. Heinemann, I.B. Hirsch, R. Hovorka, W. Jia, O. Kordonouri, B. Kovatchev, A. Kowalski, L. Laffel, B. Levine, A. Mayorov, C. Mathieu, H.R. Murphy, R. Nimri, K. Norgaard, C.G. Parkin, E. Renard, D. Rodbard, B. Saboo, D. Schatz, K. Stoner, T. Urakami, S.A. Weinzimer, M. Phillip, Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8), 1593–1603 (2019). https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
J.W. Lum, R.J. Bailey, V. Barnes-Lomen, D. Naranjo, K.K. Hood, R.A. Lal, B. Arbiter, A.S. Brown, D.J. DeSalvo, J. Pettus, P. Calhoun, R.W. Beck, A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Diabetes Technol. Ther. 23(5), 367–375 (2021). https://doi.org/10.1089/dia.2020.0535
doi: 10.1089/dia.2020.0535
pubmed: 33226840
pmcid: 8080906
K. Braune, S. O’Donnell, B. Cleal, D. Lewis, A. Tappe, I. Willaing, B. Hauck, K. Raile, Real-world use of do-it-yourself artificial pancreas systems in children and adolescents with type 1 diabetes: online survey and analysis of self-reported clinical outcomes. JMIR Mhealth Uhealth 7(7), e14087 (2019). https://doi.org/10.2196/14087
doi: 10.2196/14087
pubmed: 31364599
pmcid: 6691673
M.S. Choi, S. Lee, J. Kim, G. Kim, S.M. Park, J.H. Kim, Do-it-yourself open artificial pancreas system in children and adolescents with type 1 diabetes mellitus: real-world data. Diabetes Metab. J. 46(1), 154–159 (2022). https://doi.org/10.4093/dmj.2021.0011
doi: 10.4093/dmj.2021.0011
pubmed: 34813691
L. Petruzelkova, P. Jiranova, J. Soupal, M. Kozak, L. Plachy, V. Neuman, S. Pruhova, B. Obermannova, S. Kolouskova, Z. Sumnik, Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: a retrospective analysis. Pediatr. Diabetes 22(4), 594–604 (2021). https://doi.org/10.1111/pedi.13190
doi: 10.1111/pedi.13190
pubmed: 33576551
A. Gawrecki, D. Zozulinska-Ziolkiewicz, M.A. Michalak, A. Adamska, M. Michalak, U. Frackowiak, J. Flotynska, M. Pietrzak, S. Czapla, B. Gehr, A. Araszkiewicz, Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. PLoS One 16(4), e0248965 (2021). https://doi.org/10.1371/journal.pone.0248965
doi: 10.1371/journal.pone.0248965
pubmed: 33819289
pmcid: 8021167
R. Jeyaventhan, G. Gallen, P. Choudhary, S. Hussain, A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. Diabetes Obes. Metab. 23(8), 1989–1994 (2021). https://doi.org/10.1111/dom.14439
doi: 10.1111/dom.14439
pubmed: 33999488
A. Melmer, T. Zuger, D.M. Lewis, S. Leibrand, C. Stettler, M. Laimer, Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS). Diabetes Obes. Metab. 21(10), 2333–2337 (2019). https://doi.org/10.1111/dom.13810
doi: 10.1111/dom.13810
pubmed: 31183929
Z. Wu, S. Luo, X. Zheng, Y. Bi, W. Xu, J. Yan, D. Yang, J. Weng, Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. Ther. Adv. Endocrinol. Metab. 11, 2042018820950146 (2020). https://doi.org/10.1177/2042018820950146
doi: 10.1177/2042018820950146
pubmed: 32922721
pmcid: 7453453
M.J. Burnside, D.M. Lewis, H.R. Crocket, R.A. Meier, J.A. Williman, O.J. Sanders, C.A. Jefferies, A.M. Faherty, R.G. Paul, C.S. Lever, S.K.J. Price, C.M. Frewen, S.D. Jones, T.C. Gunn, C. Lampey, B.J. Wheeler, M.I. de Bock, Open-source automated insulin delivery in type 1 diabetes. N. Engl. J. Med. 387(10), 869–881 (2022). https://doi.org/10.1056/NEJMoa2203913
doi: 10.1056/NEJMoa2203913
pubmed: 36069869
M.J. Schoelwer, L.G. Kanapka, R.P. Wadwa, M.D. Breton, K.J. Ruedy, L. Ekhlaspour, G.P. Forlenza, E.C. Cobry, L.H. Messer, E. Cengiz, E. Jost, L. Carria, E. Emory, L.J. Hsu, S.A. Weinzimer, B.A. Buckingham, R.A. Lal, M.C. Oliveri, C.C. Kollman, B.B. Dokken, D.R. Chernavvsky, R.W. Beck, M.D. DeBoer, D.C.L.T.R.G. i, Predictors of time-in-range (70–180 mg/dL) achieved using a closed-loop control system. Diabetes Technol. Ther. 23(7), 475–481 (2021). https://doi.org/10.1089/dia.2020.0646
doi: 10.1089/dia.2020.0646
pubmed: 33689454
pmcid: 8252894
K. Braune, K.A. Gajewska, A. Thieffry, D.M. Lewis, T. Froment, S. O’Donnell, J. Speight, C. Hendrieckx, J. Schipp, T. Skinner, H. Langstrup, A. Tappe, K. Raile, B. Cleal, Why #WeAreNotWaiting-Motivations and self-reported outcomes among users of open-source automated insulin delivery systems: multinational survey. J. Med. Internet Res. 23(6), e25409 (2021). https://doi.org/10.2196/25409
doi: 10.2196/25409
pubmed: 34096874
pmcid: 8218212
American Diabetes Association Professional Practice C, 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1), S97–S112 (2022). https://doi.org/10.2337/dc22-S007
doi: 10.2337/dc22-S007